https://pro.boehringer-ingelheim.com/events/inoncology-congresses/ 2026-02-26T05:33:49+00:00 daily 1.0 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/obrixtamig-dareon7-poster-nanets-congress daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/esmo-2025-kim-poster daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/esmo-2025-laban-poster daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/sting-14801-mini-oral-presentation-esmo-congress-2025 daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/esmo-2025-pavel-poster daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/dareon-8-phase-i-trial-first-line-obrixtamig-plus-chemotherapy-and-atezolizumab-es-sclc daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/esmo-2025-wermke-poster daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/capdevilaasco-2025oral daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/wermkedareon-9-posterasco-2025 daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/wang-asco-2025oral daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/open-label-phase-ib-trial-sirpa-inhibitor-bi-765063-combination-pd-1-inhibitor-ezabenlimab-and daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/open-label-phase-ib-dose-expansion-study-assess-efficacy-cd137-fap-agonist-bi-765179-plus daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/shroffaacr-2025-cd137-14631-phase-1b-tip-poster daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/updated-results-phase-i-1456-0001-study-intratumoral-it-vsv-gp-bi-1831169-patients-advanced-solid daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/harringtonesmo-2024poster-1007p daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/first-results-intravenous-iv-vsv-gp-bi-1831169-patients-pts-advanced-solid-tumors-1456-0001-study daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/phase-i-trial-delta-ligand-3-dll3cd3-igg-t-cell-engager-obrixtamig-bi-764532-patients-pts-dll3 daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/population-pharmacokineticpharmacodynamic-modelling-cytokine-releasing-syndrome-crs-events-during-t daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/pouwsnmmi-2024poster daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/dareonr-7-phase-i-open-label-dose-escalation-and-expansion-cohort-trial-delta-ligand-dll3-targeting daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/lucassitc-2023poster daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/calvoesmo-2023poster-1030p daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/open-label-phase-i-dose-escalationexpansion-trial-anti-sirpa-monoclonal-antibody-bi-770371-patients daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/phase-i-non-randomised-open-label-multi-centre-dose-escalation-trial-bi-764532-dll3cd3-igg-t-cell daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/assessing-replicative-potential-oncolytic-virus-vsv-gp-patient-derived-tumor-biopsies-ex-vivo daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/ongoing-phase-i-trial-dll3cd3-igg-t-cell-engager-bi-764532-patients-dll3-positive-extrapulmonary daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/champiat-et-alaacr-2023poster daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/wermke-et-alalcc-2025oral-presentation daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/wermke-wclc-2024-oral daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/target-engagement-and-saturating-effects-demonstrated-quantitative-89zr-pet-imaging-therapeutic-anti daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/updated-data-phase-i-trial-dll3cd3-igg-t-cell-engager-bi-764532-patients-pts-dll3-positive-tumours daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/phase-i-trial-dll3cd3-igg-t-cell-engager-bi-764532-patients-dll3-positive-tumours-focus daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/ongoing-phase-i-trial-dll3cd3-igg-t-cell-engager-bi-764532-patients-dll3-positive-infographic daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/wermkewclc-2023oral daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/wermkeasco-2023oral daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/obrixtamig-dareon7-infographic-nanets daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/nanets-2025capdevila-et-al14381-infographic daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/esmo-2025-laban-infographic daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/esmo-2025-pavel-infographic daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/esmo-2025-peters-infographic daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/esmo-2025-wermke-infographic daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/shroff-et-alaacr-2025infographic daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/systemic-sting-agonist-bi-1703880-plus-ezabenlimab-patients-pts-advanced-solid-tumors-initial daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/phase-i-trial-delta-ligand-3-dll3cd3-igg-t-cell-engager-bi-764532-patients-pts-dll3-positive-tumors daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/phase-i-trial-dll3cd3-igg-t-cell-engager-bi-764532-patients-dll3-positive-tumors-patients-lcnec-l daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/doi-asco-2024-infographic daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/peters-asco-2024-infographic daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/phase-i-dose-escalation-trial-bi-764532-dll3cd3-igg-t-cell-engager-ezabenlimab-anti-pd-1-antibody daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/bipdf/wermke-et-alasco-2023infographic daily 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/library 2026-02-26T05:34:25+00:00 always 0.5 https://pro.boehringer-ingelheim.com/events/inoncology-congresses/scientific-information 2026-02-26T05:34:48+00:00 always 0.5